Lyra Therapeutics, Inc.

LYRASEC EDGAR

Surgical & Medical Instruments & Apparatus(DE)CIK: 1327273

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$1.6M	$1.4M	$285.0K	$285.0K	—
Research and Development Expense	$48.0M	$38.8M	$29.7M	$12.5M	$12.0M
Operating Expenses	$68.7M	$57.7M	$43.9M	$22.2M	$16.5M
Operating Income (Loss)	-$67.1M	-$56.3M	-$43.6M	-$22.2M	-$16.5M
Nonoperating Income (Expense)	$4.5M	$1.0M	$102.0K	$82.0K	$213.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$62.6M	-$55.3M	-$43.5M	—	—
Income Tax Expense (Benefit)	$59.0K	$13.0K	$13.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$142.6M	$110.0M	$54.9M	$80.8M	$15.0M
Assets, Current	$104.8M	$100.8M	$47.9M	$75.9M	$10.1M
Cash and Cash Equivalents, at Carrying Value	$22.4M	$32.5M	$45.7M	$74.6M	$9.8M
Liabilities	$53.2M	$29.2M	$20.6M	$6.3M	$7.6M
Liabilities, Current	$19.6M	$14.5M	$18.2M	$4.9M	$5.2M
Accounts Payable, Current	$3.1M	$2.6M	$3.1M	$922.0K	$1.1M
Stockholders' Equity Attributable to Parent	$80.8M	$34.3M	$74.5M	-$123.3M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$63.3M	-$43.4M	-$25.8M	-$21.1M	-$13.8M
Net Cash Provided by (Used in) Investing Activities	-$12.6M	-$65.0M	-$3.4M	-$1.8M	-$211.0K
Net Cash Provided by (Used in) Financing Activities	$65.7M	$96.3M	$359.0K	$87.7M	-$115.0K
Payments to Acquire Property, Plant, and Equipment	$1.0M	$164.0K	$3.4M	$1.8M	$211.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)